Randomized controlled phase IV trial of combination aflibercept and Kallidinogenase for neovascular age-related macular degeneration

Randomized controlled phase IV trial of combination aflibercept and Kallidinogenase for neovascular age-related macular degeneration - Combined trial of aflibercept and Kallidinogenase for neovascular age-related macular degeneration

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011703

Enrollment

Registered

2013-09-10

Start date

2013-09-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-related macular degeneration

Interventions

Kallidinogenase internal use(+) 20cases Kallidinigenase internal use(-) 20cases

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects were eligible if the following criteria were met: 1) Intravitreal injection of aflibercept for neovascular age-related macular degeneration 2) Age>40years 3) Ability to provide written informed consent for this study

Exclusion criteria

Exclusion criteria: 1)internal use of kallidinogenase 2)intravitreal anti-VEGF therapy or intravitreal steroid therapy in the study eye within the past 6 months 3)photodynamic therapy or focal laser in the study eye within the past 6 months 4)surgical therapy in the study eye within the past 6 months 5)past allergic reaction for kallidinigenase 6)pregnancy (positive pregnancy test) women 7)participation in another simultaneous medical investigation or trial within the past 3 months 8)other conditions that the investigator believed would pose a significant hazard to the subject if investigational therapy were initiated

Design outcomes

Primary

Measure	Time frame
central retinal thickness	—

Countries

Japan

Contacts

Public ContactHisashi Matsubara

Mie University Graduate School of Medicine Department of Ophthalmology

ganka@clin.medic.mie-u.ac.jp059-232-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026